false
Catalog
2023 World Conference on Lung Cancer (Posters)
EP11.02. Dostarlimab + CT vs Pembrolizumab + CT in ...
EP11.02. Dostarlimab + CT vs Pembrolizumab + CT in Metastatic Non-Squamous NSCLC: Asian Subgroup Analyses of the PERLA Trial - PDF(Abstract)
Back to course
Pdf Summary
This document is a summary of a presentation at the WCLC 2023 conference titled "Dostarlimab CT vs Pembrolizumab CT in Metastatic Non-Squamous NSCLC: Asian Subgroup Analyses of the PERLA Trial." The presentation discusses the use of programmed cell death protein-(ligand) 1 (PD-(L)1) inhibitors in the treatment of metastatic non-squamous non-small cell lung cancer (NSCLC). The study compares the efficacy and safety of dostarlimab (dostar) chemotherapy (CT) versus pembrolizumab (pembro) CT in patients with first-line metastatic non-squamous NSCLC. The PERLA trial is a global, randomized, Phase II double-blind study.<br /><br />The presentation focuses on the subgroup analyses of the Asian population. The Asian population was the second largest in the study, with 44 patients. The objective response rate (ORR) for dostar CT was 43%, with 1 complete response (CR) and 9 partial responses (PRs). The ORR for pembro CT was 29%, with 1 CR and 5 PRs. The difference in response rate between the two groups was 13.8%. <br /><br />The conclusion of the study is that dostar CT showed comparable efficacy to pembro CT in first-line metastatic non-squamous NSCLC in Asian patients with no actionable mutations. <br /><br />The study was funded by GSK and editorial support was provided by Fishawack Health, funded by GSK. <br /><br />Keywords: non-small cell lung cancer, programmed cell death protein-(ligand) 1, PERLA.
Asset Subtitle
DAE HO LEE
Meta Tag
Speaker
DAE HO LEE
Topic
Metastatic NSCLC: Immunotherapy - Prospective
Keywords
non-small cell lung cancer
programmed cell death protein-(ligand) 1
PERLA
dostarlimab
pembrolizumab
chemotherapy
metastatic
Asian population
efficacy
safety
×
Please select your language
1
English